Discovery, Structure–Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4-Reference-Cited by-同舟云学术

Discovery, Structure–Activity Relationship, and Antiparkinsonian Effect of a Potent and Brain-Penetrant Chemical Series of Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4

Published:2017-10-12 Issue:20 Volume:60 Page:8515-8537
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Charvin Delphine¹^ORCID,Pomel Vincent¹,Ortiz Millan¹,Frauli Mélanie²,Scheffler Sophie²,Steinberg Edith²,Baron Luc²,Deshons Laurène²,Rudigier Rachel³,Thiarc Delphine³,Morice Christophe³,Manteau Baptiste²,Mayer Stanislas²,Graham Danielle⁴,Giethlen Bruno³,Brugger Nadia⁴,Hédou Gaël⁴,Conquet François¹,Schann Stephan²

Affiliation:

1. Prexton Therapeutics, 14 Chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland

2. Domain Therapeutics, 850 Boulevard Sébastien Brant, 67400 Illkirch-Strasbourg, France

3. Prestwick Chemical, 220 Boulevard Gonthier d’Andernach, 67400 Illkirch-Strasbourg, France

4. EMD Serono, 45A Middlesex Turnpike, Billerica, Massachusetts 0182, United States

Funder

EMD Serono

Fonds Unique Interminist?riel

Prexton Therapeutics

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b00991

Reference50 articles.

1. The scientific and clinical basis for the treatment of Parkinson disease (2009)

2. An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment

3. l-Dopa-Induced Dyskinesia—Clinical Presentation, Genetics, and Treatment

4. Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances and Insights in Positron Emission Tomography Tracers for Metabotropic Glutamate Receptor 4 Imaging;Journal of Medicinal Chemistry;2024-06-26

2. Targeting mGluR group III for the treatment of neurodegenerative diseases;Biomedicine & Pharmacotherapy;2023-12

3. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials;Signal Transduction and Targeted Therapy;2023-09-06

4. Foliglurax, a positive allosteric modulator of the metabotrophic glutamate receptor 4, protects dopaminergic neurons in MPTP-lesioned male mice;Brain Research;2023-06

5. Allosteric modulation of G protein-coupled receptor signaling;Frontiers in Endocrinology;2023-02-16